Genmab — Oktober 2019
-
Meet Oncology Venture CFO Henrik Moltke in an online interactive Q&A session about the company and its Q3 Report.
6th of November 16.00 CET. https://www.proinvestor.com/index.php?p=q-and-a&groupid=110 -
D-RVD a potential new standard of care https://twitter.com/slentzsch/status/1187449273933336576?s=21
-
7 reasons NOT to treat smoldering myeloma patients https://twitter.com/slentzsch/status/1187402586154065923?s=21
-
God morgen.
-
Tusinde tak for link GB.
-
The headline of that poster was a little different: Not to treat the MAJORITY of SMM pts. Xactly, only high-risk SMM, about 15% of all SMM. No 7: Yes, high-risk will in the future be considered as symptomatic MM - and treated. The rest: WAS-"treatment". Wait And See.
-
God morgen. Tak for dit fine arbejde Helge. Jeg har nu lige doneret lidt til fortsat fremgang for sitet.
-
Tusinde tak Peter.
-
Flere af denne slags overskrifter: https://medwatch.dk/Medicinal___Biotek/article11658769.ece?fbclid=IwAR3aZR_Rww3uTZZI6TiwesMYJ_hGPECFpj8d8SiWclisAeJ0bKh2WfzAJRA
-
E L: Could be: O. Landgren: The incidence and prevalence of smoldering multiple myeloma in the population is not well defined. The best available estimates to date come from a recent study by Kristinsson and colleagues who used the Swedish Myeloma Registry from 2008 to 2011 with a total of 2494 patients with any type of newly diagnosed myeloma showing that 360 (14.4%) had smoldering multiple myeloma. Among patients with smoldering multiple myeloma, 104 (28.8%) had high-risk smoldering mm
-
-
2 small new trials - https://clinicaltrials.gov/ct2/show/NCT04140162?term=daratumumab+OR+ofatumumab+OR+tisotumab+OR+Genmab+OR+arzerra+OR+duobody&lupd_s=10%2F25%2F2019&draw=2&rank=4 - https://clinicaltrials.gov/ct2/show/NCT04139304?term=daratumumab+OR+ofatumumab+OR+tisotumab+OR+Genmab+OR+arzerra+OR+duobody&lupd_s=10%2F25%2F2019&draw=2&rank=3
-
-
God morgen.
-
USA: Højeste budgetunderskud i 7 år. Medicare, forsvarsudgifter og renter fylder mest. Se tallene fra finansdepartementet. https://fiscal.treasury.gov/files/reports-statements/mts/mts0919.pdf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind